PMID: 15218809Jun 29, 2004Paper

Effect of drugs in secondary disease progression in patients with multiple sclerosis

Multiple Sclerosis : Clinical and Laboratory Research
L Kappos

Abstract

Secondary progressive multiple sclerosis (SPMS) is a form of MS characterized by continuously worsening disability with or without superimposed relapses that occurs after a variable period of relapsing remitting disease and results in limited ambulation for almost all patients. The use of interferon beta (IFN beta) for immunomodulation in patients with SPMS has been evaluated in four recent clinical trials: The European multicentre trial on IFN beta-1b in SPMS (EUSPMS), the Secondary Progressive Efficacy Trial of Rebif (IFN beta-1a) in MS (SPECTRIMS), the North American Study of IFN beta-1b in SPMS (NASPMS), and the International MS Secondary Progressive Avonex Clinical Trial (IMPACT). EUSPMS was the only trial to demonstrate a significant positive effect of therapy on disease progression as measured by the expanded disability status scale (EDSS). However, results from all studies demonstrated significant positive effects of treatment on relapse, T2 lesion load, and gadolinium enhancement. Immunomodulation with IFN beta has the potential to significantly slow disease progression and improve quality of life for patients with SPMS. While results with monthly i.v. Ig were disappointing, positive effects on disease progression have...Continue Reading

References

Jul 1, 1988·Acta Neurologica Scandinavica·J M MinderhoudA J Prange
Aug 1, 1987·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·B G Weinshenker, G C Ebers
Nov 1, 1993·Journal of Neurology, Neurosurgery, and Psychiatry·R D CurrierE F Meydrech
Jun 4, 1999·Brain : a Journal of Neurology·G R CutterE Willoughby
Dec 22, 1999·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·W I McDonald, M A Ron
Feb 15, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·A Bayas, P Rieckmann
Apr 25, 2000·Drugs·B Weinstock-Guttman, L D Jacobs
Aug 10, 2000·Italian Journal of Neurological Sciences·L La MantiaC Milanese
Jun 13, 2001·Neurology·UNKNOWN Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group
Jun 13, 2001·Neurology·D K LiUNKNOWN University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group
Jun 16, 2001·Brain : a Journal of Neurology·F BarkhofUNKNOWN European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis
Jul 11, 2001·Neurology·G L MancardiUNKNOWN Italian GITMO-NEURO Intergroup on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Oct 18, 2001·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·A LugaresiD Gambi
Nov 15, 2001·Annals of Neurology·J W PrineasB P Morgan
Nov 28, 2001·Neurology·J A FreemanUNKNOWN European Study Group on Interferon-beta1b in Secondary Progressive MS
Dec 12, 2001·Neurology·L KapposUNKNOWN European Study Group in Interferon beta-1b in Secondary-Progressive MS
Jan 31, 2002·Annual Review of Medicine·B Mark Keegan, John H Noseworthy
May 29, 2002·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·L Durelli, G Isoardo
Jul 20, 2002·Clinical Neurology and Neurosurgery·Maura PugliattiGiulio Rosati
Aug 27, 2002·Journal of Neurology·A FassasUNKNOWN Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation)
Sep 11, 2002·Neurology·J A CohenUNKNOWN IMPACT Investigators
Oct 3, 2002·Multiple Sclerosis : Clinical and Laboratory Research·R A RudickS Reingold
Nov 28, 2002·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P S SorensenM Lee
Dec 31, 2002·Lancet·Hans-Peter HartungUNKNOWN Mitoxantrone in Multiple Sclerosis Study Group (MIMS)
Jan 18, 2003·Progress in Neurobiology·Martin Stangel, Hans-Peter Hartung
Mar 5, 2003·Brain : a Journal of Neurology·Christian ConfavreuxPatrice Adeleine
Aug 28, 2003·Lancet Neurology·Jerry S WolinskySidney E Grossberg

❮ Previous
Next ❯

Citations

Nov 17, 2010·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·B SvendsenJ H Aarseth
Mar 16, 2007·Journal of Neurology·Jordi RíoXavier Montalban
Mar 18, 2010·International Review of Psychiatry·Odysseas KargiotisPanagiotis Papathanasopoulos
Oct 22, 2013·The Spine Journal : Official Journal of the North American Spine Society·Markus R KoniecznyThomas M Frangen
Nov 17, 2011·European Neurology·Jens Peter ReeseRichard Dodel
Jun 21, 2008·Multiple Sclerosis : Clinical and Laboratory Research·S MindenJ Outley
Jun 18, 2008·Acta Neurologica Scandinavica. Supplementum·Kjell-Morten Myhr
Sep 20, 2005·Journal of Neurology·Ludwig KapposRaija L P Lindberg
Mar 1, 2019·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Sarah L MindenLisa I Iezzoni

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.